Last reviewed · How we verify
Liposomal daunorubicin
Liposomal daunorubicin is an anthracycline chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cancer cell death.
Liposomal daunorubicin is an anthracycline chemotherapy agent encapsulated in liposomes that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cancer cell death. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | Liposomal daunorubicin |
|---|---|
| Also known as | Daunoxome, DaunoXome, daunorubicin liposomal, liposomal daunorubicin |
| Sponsor | University of Birmingham |
| Drug class | Anthracycline chemotherapy agent |
| Target | Topoisomerase II, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Daunorubicin is a topoisomerase II inhibitor that intercalates between DNA base pairs, preventing DNA replication and transcription. The liposomal formulation encapsulates the drug in lipid vesicles, which improves pharmacokinetics, reduces systemic toxicity, and enhances delivery to tumor tissues. This formulation allows for higher doses with potentially improved therapeutic index compared to conventional daunorubicin.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
Common side effects
- Cardiotoxicity
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Mucositis
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal daunorubicin CI brief — competitive landscape report
- Liposomal daunorubicin updates RSS · CI watch RSS
- University of Birmingham portfolio CI